Diagnosing Ventilator-Associated Pneumonia (VAP) remains challenging. Although several guidelines exist, including the American Thoracic Society (ATS) and European Respiratory Society (ERS) guidelines, these are not fully aligned and are mainly based on clinical signs and symptoms rather than aiming to identify the causative pathogen. Despite the recent availability of rapid molecular diagnostics, culture remains the standard for species identification and subsequent Antimicrobial Susceptibility Testing (AST), but comes with a low specificity and a long time-to-result which makes it impractical for implementation in such guidelines, especially for initial treatment. Early confirmation of VAP however significantly enhances the appropriate management of the disease, reducing morbidity and mortality. Authors therefore set out to identify the demand side from a clinical perspective and to match this with the currently available innovative diagnostic solutions.
Analysis of current status of Rapid Diagnostics test for the Ventilator-Associated Pneumonia (VAP) diagnosis
Published on 23.09.2020